Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Gilead Sciences Announces Completion of Acquisition of CymaBay
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead
Why is CymaBay (CBAY) Stock Up 25% Today?
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
Gilead to buy CymaBay Therapeutics for $4.3 billion
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Drugmaker Gilead to acquire CymaBay for $4.3 bln
Gilead strikes deal to acquire CymaBay for $4.3 billion
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
Does CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?
CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call Transcript
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
CymaBay Therapeutics to Present at Upcoming Investment Conferences
CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
CymaBay's RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio
Why CymaBay Therapeutics Stock Is Sinking This Week
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
Why CymaBay Therapeutics Stock Popped Again Today
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
CymaBay: Positive Phase 3 Data And Competitive Advantage Established
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
Why CymaBay Therapeutics Stock Is Jumping Today